Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation

Zhang X., Tian Y., Ren X., Liu J., Wang G.

Animal Study on Chronic Kidney Disease, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Diabetol Metab Syndr (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41340158
PMCID
PMC12676836
DOI
10.1186/s13098-025-02010-1

Abstract (original English)

BACKGROUND: Obesity is a risk factor for chronic kidney disease (CKD). One of the main features of obesity-related glomerulopathy (ORG) is the chronic low-grade inflammatory state. Herein, we aimed to explore the inflammatory proteins that potentially serve as mediators between obesity and CKD by Mendelian randomization (MR) analysis, and to validate the findings by clinical research and animal experiments. METHODS: Two-step MR and mediation analyses were performed to assess the causal relationships between obesity-related traits and circulating inflammatory proteins and CKD. After identifying Oncostatin M (OSM) as the potential mediator, serum OSM levels of human participants with normal weight, overweight or obesity were assessed. Expression of OSM receptor (OSMR) in the human kidney was validated using publicly available scRNA-seq data. The protein expression and activation of OSMR in the kidneys of obese mice fed a high-fat diet (HFD) were validated by Western blotting. RESULTS: Circulating OSM level is a potential mediator between body mass index (BMI) and CKD, with a mediated proportion of 4.48%. In the clinical study, serum OSM levels were elevated in obese individuals and associated with both BMI and proteinuria. The scRNA-seq analysis found elevated OSMR expression in obese kidneys, with the highest expression level in endothelial cells. The in vivo experiment showed i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research